cyrilzakka/clinical-trials huggingface dataset:
Psychometric Evaluation of Commonly Used Measures in Stroke

Purposes: The aim of this study is to examine the psychometric properties (e.g. test-retest reliability, random measurement error, practice effect, and responsiveness) of the commonly used measures in patients with stroke using medical record review.

The investigators anticipate reviewing 1000 stroke patients' medical record from a medical center in Taiwan. The medical record will be reviewed by an experienced and well-trained occupational therapist.

The investigators anticipate reviewing 1000 stroke patients' medical record (from 2018/6/1 to 2021/6/30) from a medical center in Taiwan. The medical record will be reviewed by an experienced and well-trained occupational therapist. The study was approved by the local institutional review board. Because the targeted populations for examining the test-retest reliability and responsiveness were different, the inclusion criteria were listed separately below.

Test-retest reliability Chronic stroke patients' data was reviewed to examine the test-retest reliability. The participants met the following criteria: (1) diagnosis of cerebral hemorrhage or cerebral infarction, (2) age ≥ 20 years, and (3) stroke onset ≥ 6 months (first and recurrent stroke included).

Responsiveness Subacute stroke patients' data was reviewed to examine the responsiveness. The participants met the following criteria: (1) diagnosis of cerebral hemorrhage or cerebral infarction, (2) age ≥ 20 years, and (3) stroke onset \< 3 months (first and recurrent stroke included).

Eligibility Criteria:
Inclusion criteria for test-retest reliability group (Chronic stroke patients' medical record was reviewed to examine the test-retest reliability) :

* Cerebral hemorrhage or cerebral infarction.
* Age ≥ 20 years.
* Stroke onset ≥ 6 months (first and recurrent stroke included).

Inclusion criteria for responsiveness group (Subacute stroke patients' medical record was reviewed to examine the responsiveness):

* Cerebral hemorrhage or cerebral infarction.
* Age ≥ 20 years.
* Stroke onset \< 3 months (first and recurrent stroke included).

Exclusion criteria

• Patients' diagnosis is not stroke.
Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma

This is a multicenter,open-label trial to evaluate activity and safety of the investigational intensive in HIV+ patients with Burkitt's lymphoma.

Experimental treatment consists of an induction phase followed by a consolidation or intensified phase according to tumor response.

Until recently, the immuno-compromised state of patients with concomitant HIV/AIDS and BL was thought to limit the ability to administer intensive chemotherapeutic regimens due to infection rate. However, the advent of highly active antiretroviral therapy (HAART) and evidence in diffuse large B-cell lymphomas that HIV-positive patients can tolerate standard chemotherapeutic regimens with improved outcomes have led investigators to treat HIV-positive patients with the same intensive chemotherapy regimens used to treat immuno-competent patients. Data suggest that these current approaches, along with supportive care, may result in improved patient outcomes, similar to those in the immuno-competent patient population.

The activity of feasibility of the proposed program will be assessed in HIV+ patients with Burkitt lymphoma with the aim to improve tolerability, minimize source consuming and supporting treatment and redu ce late sequels. Available combinations in this setting are really source demanding and toxic combinations showing high rates of septic complication and a treatment-related mortality of near 20%.

Eligibility Criteria:
Inclusion Criteria:

* Histologic diagnosis of Burkitt's lymphoma (WHO 2008)
* HIV sero-positivity
* Age ≥18 and ≤60 years
* ECOG-PS ≤3

Exclusion Criteria:

* CNS parenchymal involvement
* Absolute neutrophil count \<1.000 cells/μL and platelets count \<75 × 109/L (Burkitt unrelated)
* Creatinine \>1,5N (Burkitt unrelated)
* SGOT and/or SGTP \>2,5N (Burkitt unrelated)
* Bilirubin \>2N (Burkitt unrelated)
* Severe psychiatric illness or any other clinical, social or psychological condition that could interfere with patient's adherence and compliance
* Significant cardiac disease or acute myocardial infarction in the last 12 months
* Severe active infection (except for HBV and/or HCV co-infection)
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites

Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF accurately.

We will assess IVC dynamics, LV systolic function \[LV ejection fraction (EF) \& cardiac output (CO)\], and diastolic dysfunction (E/e', e' and E/A ratio) and urinary biomarkers (cystatin C and NGAL) in patients with cirrhosis and Refractory Ascites.

The decrease in systemic vascular resistance (SVR) and redistribution of blood volume with reduced intravascular volume compartment and third space fluid losses. Systemic vasodilatation is compensated by an increase in cardiac output (CO) in the initial stages of compensated cirrhosis. However, as the stage of liver cirrhosis progresses to decompensation, more prominent arterial vasodilatation and reduced SVR leads to a fall in CO. Thus, the cardiac homeostat is reset in a cirrhotic hyperdynamic circulation, wherein an increased heart rate, and therefore, increased cardiac output will no longer be able to compensate for the reduced mean arterial pressure (MAP), and decreased blood volumes in central venous territories.18 Consequent activation of vasoconstrictor systems including renin-angiotensin-aldosterone, vasopressin and the sympathetic nervous system comes into play to maintain the intravascular blood volume and pressure. These compensatory pathways cause an increase in sodium and water retention resulting in refractory ascites and hepatorenal syndrome (HRS). In critically ill patients with cirrhosis, the limited cardiac reserve is further stressed, CCM and heart failure may be diagnosed for the first time when the patient develops sepsis or septic shock.

Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis accurately. We will assess IVC dynamics, LV systolic function \[LV ejection fraction (EF) \& cardiac output (CO)\], and diastolic dysfunction (E/e', e' and E/A ratio) in patients with cirrhosis ACLF and refractory ascites

Definition of CCM is as per updated CCMC criteria of 2020.

Eligibility Criteria:
Inclusion Criteria:

* Cirrhosis of any Etiology
* Patient with Refractory Ascites

Exclusion Criteria:

* Hepatocellular carcinoma
* Patients with active variceal bleeding
* HIV or severe immunocompromised state
* Chronic kidney disease (CKD) on renal replacement therapy (RRT),
* Previous transjugular intra hepatic portosystemic shunt (TIPS)
* Porto-pulmonary hypertension,
* Coronary artery disease
* Congenital or valvular heart disease
* Prosthetic cardiac valves
Diets in Symptom Relief and the Influence of Quality of Life in People With Irritable Bowel Syndrome

Subjects with confirmed diagnosis of Irritable Bowel Syndrome will be blinded and randomly assigned to one of two groups, the low FODMAP diet or the conventional IBS diet group. They will be referred to do three hydrogen breath tests prior to diet education. Upon completion, subjects will attend dietitian consultations at Week 0, 6 and 10 for diet assessment, education and reinforcement. At Week 4 and 8, dietitians will telephone patients to check on diet compliance and answer any diet question. Two sets of questionnaires, the IBS Global Improvement Scale and the IBSQOL will be given to patients to complete before each dietitian visit at week 0, 6 and 10. Two sample t-test and Chi square test will be used to test the difference between the two groups and the association between breath tests results and responds to the two diets.

1. Subjects who are interested will be interviewed and screened for IBS with Rome Ⅲ criteria by the principle investigator. Research information will be explained in length and consent form will be signed if they agreed to participate
2. Subjects will be blinded and randomly assigned to Conventional IBS diet group (A) or Low FODMAP diet group (B)
3. 3 Breath tests (lactulose, fructose, lactose) will be carried out for all subjects before diet education
4. Subjects will be asked to come to the dietitians clinic and receive the first one hour diet education (including diet assessment \& diet education) and two times thirty minutes follow-up appointments with the dietitians at Week 0, 6 and 10, respectively
5. Subjects will be asked to record their food intake and signs and symptoms onto a food record book
6. Subjects will be asked to fill out the IBS Global Improvement Scale and the IBSQOL questionnaire at Week 0, 6 \& 10
7. At week 4 and week 8, telephone interviews will be conducted by the dietitians to reinforce diets and answer diet questions
8. Results of IBS Global Improvement Scale and IBSQOL questionnaire will be analyzed using two sample t-test to test the difference between control and treatment group
9. Chi square test will be used to look at the association between breath tests results and responds to the two diets

Eligibility Criteria:
Inclusion Criteria:

* Adults \>18 years
* Confirmed IBS (after meeting Rome Ⅲ criteria)
* Hong Kong Chinese

Exclusion Criteria:

* Age \<18 years
* Pregnancy
* Other ethnicities besides Hong Kong Chinese
* Significant GI co-morbidities such as Inflammatory Bowel Disease, Coeliac disease, significant diverticular disease, history of GI cancer, GI resection and GI reconstruction
Transconjunctival Sutureless 25-Gauge Vitrectomy

The aim of this study was to evaluate the role of 25-gauge transconjuntival sutureless vitrectomy (TSV) in patients with persistent vitreous floaters who underwent multifocal intraocular lens (IOL) implantation.

Purpose: The aim of this study was to evaluate the role of 25-gauge transconjuntival sutureless vitrectomy (TSV) in patients with persistent vitreous floaters who underwent multifocal intraocular lens (IOL) implantation.

Setting: Hospital Oftalmológico de Brasília, Brasília, DF, Brazil.

Methods: Fourteen eyes of 11 patients with multifocal IOL implant associated with vitreous opacities that underwent 25-gauge vitrectomy were prospectively analyzed. Information collected included near and distance uncorrected visual acuity (UCDVA), best corrected distance visual acuity (BCDVA), and the spherical equivalent (SE) before and 3 months after vitrectomy. Patients were questioned about surgery satisfaction and visual improvement after vitrectomy.

Eligibility Criteria:
Inclusion Criteria:

* disabling vitreous floaters
* Age-related cataract Unsatisfactory correction with glasses

Exclusion Criteria:

* central endothelial cell count less than 2000 cells/mm2
* glaucoma or intraocular pressure greater than 21 mmHg
* amblyopia
* retinal abnormalities
* diabetes mellitus
* steroid or immunosuppressive treatment
* connective tissue diseases
Fructosamine as a Predictor of Surgical Outcomes in Total Joint Arthroplasty A Prospective Multi-center Study

A prospective multicenter study including all patients undergoing elective total hip (THA) or knee (TKA) arthroplasty (primary and revision). Patients will be screened for glycemic control using HbA1c levels, fructosamine levels, and blood glucose levels. Blood samples will be obtained at the preadmission testing (PAT) within 30 days of surgery. On postoperative day 1 (POD-1), morning glucose levels will be obtained for all patients as well. Patients will be followed up for 90 days postop.

Study aims

1. To examine the association between serum fructosamine levels and the risk for adverse outcomes (mainly PJI) following TJA among patients with and without diabetes.
2. To compare the utility of fructosamine levels to HbA1c in predicting adverse outcomes.
3. To determine the "best" threshold of fructosamine to determine adverse outcomes.


Eligibility Criteria:
Inclusion Criteria:

all patients undergoing elective total hip (THA) or knee (TKA) arthroplasty (primary and revision)

Exclusion Criteria:

None
CAPERE Thrombectomy System Post-Market Clinical Follow Up Study

A prospective, single-arm, non-blinded study, intending to collect and evaluate data in up to forty (40) human subjects with acute thrombosis, treated with the CAPERE™ Thrombectomy System.

A prospective, single-arm, non-blinded study, intending to collect and evaluate data in up to forty (40) human subjects with acute thrombosis, treated with the CAPERE™ Thrombectomy System.

Subjects will be evaluated based on VEINES QoL survey pre- and post-treatment (30-days).

Eligibility Criteria:
Inclusion Criteria:

* Patients who are greater than or equal to 18 years of age
* Patients with clinical signs, symptoms and presentation consistent with acute thrombosis; onset of symptoms \< 14 days
* Patients cleared medically for invasive endovenous procedures

Exclusion Criteria:

* Patients with IVC filter in area to be treated
* Patients who are \< 18 years of age.
* Known anaphylactic reaction of radiographic contrast agents that cannot be pre- treated
* Imaging evidence or other evidence that suggests the participant is not appropriate for mechanical thrombectomy intervention
* Female who is pregnant or nursing
* Concurrent participation in another investigational drug or device treatment study
COPD Scoring Systems in ICU

The aim of our study was to assess the performance of APACHE II and SAPS II scoring methods in predicting out come among critically ill COPD patients admitted to the respiratory intensive care unit (RICU) at Assiut University Hospital

Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating airway disease that results in a large burden, both medically and financially. It affects millions of people around the world and causes great rates of morbidity and mortality. This burden is anticipated to increase with an estimated 5.8 million deaths annually by 2030 \[1\].

A large proportion of patients with COPD usually require admission to the ICU and it may be helpful to recognize patients at the time of admission who are probable to have bad consequence, so that these patients can be managed violently \[2 There are many ICU scoring models, and numerous new systems are being progressed to assess severity of illness in ICU patients. The use of scoring models particularly developed for patient evaluation at the time of ICU entry has decreased many troubles and helped therapy delineation.

Acute Physiology and Chronic Health Evaluation II (APACHE II) and Simplified Acute Physiology Score II (SAPS II) scoring systems are the two models that are greatly used by the majority of ICUs to forecast the clinical consequence \[3

Eligibility Criteria:
Inclusion Criteria All patients involved have undergone full history with special stress on age, gender, special habits, and associated diseases. Information such as the patient's need for mechanical ventilation as well as the duration of lodging in the ICU was entered. Routine laboratory variables were also registered. Patients were followed up until their outcome was determined. The outcome was decided according to the mortality within the ICU and recorded as survivors and nonsurvivors. Scores of

APACHE II and SAPS II were calculated:

-

Exclusion Criteria:

* Excluded from this study were COPD patients admitted to the ICU because of any other underlying problem such as those with acute cardiac situation, patients with respiratory failure due to other diseases along with COPD, patients who lasted less than 24 h in the ICU, and those who died before the completion of data collection.
Therapy of Preconditioned Autologous BMMSCs for Patients With Ischemic Heart Disease

The purpose of the present study is to evaluate the efficacy of the preconditioned autologous bone marrow mesenchymal stem cells for patients with ischemic heart diseases.


Eligibility Criteria:
Inclusion Criteria:

* Age under 75;
* Clinical diagnosis of acute Myocardial Infarction, chronic Myocardial Infarction and Ischemic Cardiomyopathy
* NYHA (New York Heart Association) grade: III-IV, LVEF (left ventricular ejection fraction): 25-50%;
* No infection diseases including HBV (hepatitis B virus), HCV (hepatitis C virus ), syphilis and AIDS;
* No psychiatric illnesses and speaking dysfunction;
* Informed consent.

Exclusion Criteria:

* More than 75 years old;
* LVEF\<24%;
* Unstable hemodynamics, shock;
* Severe infection;
* Patients have tumor or other lethal diseases (expectation of life\<6 months);
* Radiation patients;
* hematopoietic malignancy including Haemophiliacs;
* Anemia (Hb\<100g/L);
* The other clinical trial participants within one month;
* Abnormal increasing of the blood biochemical indicators that is not explained by the conditions;
* Informed refusal.
PPI Sequencing Study

The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a change in treatment.


Eligibility Criteria:
Inclusion Criteria:

* Persisting symptoms of GORD despite previous treatment with a full dose proton pump inhibitor
* Informed consent
* Over 18 years of age

Exclusion Criteria:

* Current course of Proton Pump inhibitor treatment for more than 8 weeks prior to enrolment in the study;
* More than 1 other course of PPI treatment in the previous 12 month;
* Previous use of esomeprazole;
* Presence of alarm symptoms.
Effectiveness of Routine Physical Therapy With and Without Thoracic Mobility Exercises in Chronic Neck Pain

There is a limited data available on the effectiveness of thoracic mobility exercises in chronic neck pain and there is a need to determine these exercises in chronic neck pain because chronic neck pain has significant effects on the surrounding muscles of the neck and cervical spine and along with the muscles of shoulder and arm. So the mobility exercises of any region around the neck area can reduce neck pain because these structures are interlinked anatomically and functionally aspects.


Eligibility Criteria:
Inclusion Criteria:

* 18 years old and over
* A medical diagnosis of chronic cervical pain (more than 3 months of cervical pain evolution)
* Positive flexion rotation test

Exclusion Criteria:

* cervical radiculopathy
* History of Trauma, any Surgery, any Systemic diseases, any Fractures, congenital diseases.
* Dislocation.
Comparison of Inflight First Aid Performed by Cabin Crew Members and Medical Volunteers

Since the number of air travelers, including the elderly and passengers with an underlying disease, is increasing every year, the number of inflight emergency patients is expected to increase as well. The investigators attempted to identify the incidence and types of inflight medical emergencies and analyze the first aid performed by cabin crew members or medical volunteers in flights by an Asian airline. The investigators also investigated the causes of inflight deaths and aircraft diversions.


Eligibility Criteria:
Inclusion Criteria:

* Inflight medical emergencies from 2009 to 2013

Exclusion Criteria:

* Events that occurred before takeoff or after landing
Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis

This purpose of this study is to determine the lowest effective concentration of intralesional triamcinolone acetonide in the treatment of nail psoriasis.


Eligibility Criteria:
Inclusion Criteria:

* At least 18 years of age
* Diagnosed with nail psoriasis in at least 2 fingernails
* Willing to give written informed consent and able to adhere to procedures and visit schedules
* Must consent to having the fingernails photographed during the study period

Exclusion Criteria:

* Subject with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with study evaluations or optimal participation in the study. This is including, but not limited to: immunodeficiency, onychomycosis, any other nail condition other than psoriasis, allergy to triamcinolone acetonide, local anesthetic, normal saline, or any other material used for procedures
* Subject who has received radiation therapy, chemotherapy, and/or immunosuppressive drugs within 6 months of study, and/or oral corticosteroids for \>1 month within the 6 months of study (exception: inhaled steroids)
* Subject known to have received treatment with investigational drugs or devices within 30 days prior to enrollment into this study
* Subject who is unwilling to abstain from any cosmetic nail treatments outside those provided by the study clinic, beyond basic nail trimming (i.e. no spa nail treatments, no nail polish use, no other topical prescription nail medication)
* Subject who is unwilling to abstain from any medical nail treatments on their nails other than the study intervention (i.e. topical steroids, anti-fungal creams) for the duration of the study intervention and for duration of the washout period (if applicable)
* Subject who is part of the staff personnel directly involved with this study or a family member of the investigational study staff